Is there a relationship between NR-2 antibody peptide level and diagnosis, prognosis and coma scores in acute ischemic stroke?
| dc.contributor.author | Tuncar, Alpay | |
| dc.contributor.author | Cander, Başar | |
| dc.contributor.author | Küçükceran, Kadir | |
| dc.contributor.author | Yerlikaya, Fatma Hümeyra | |
| dc.date.accessioned | 2022-10-03T08:31:16Z | |
| dc.date.available | 2022-10-03T08:31:16Z | |
| dc.date.issued | 2022 | |
| dc.department | ALKÜ | |
| dc.description.abstract | Aim: This study aimed to demonstrate the diagnostic and prognostic value of NR-2 peptides as a biomarker in acute ischemic stroke and to evaluate their correlation with the Glasgow Coma Scale (GCS) and the National Institutes of Health Stroke Scale (NIHSS). Materials and Methods: The importance of NR-2 peptide level in diagnosis and prognosis in acute stroke was investigated cross-sectional and prospectively. The study included 101 patients, who presented to a tertiary healthcare facility and were diagnosed with acute stroke, and 57 healthy controls. In the whole study population, serum NR-2 peptide levels were measured using the ELISA method. Results: The NR-2 peptide level was 6.32 ± 8.30 in the patient group and 3.91 ± 1.64 in the study group. The NR-2 peptide level was significantly higher in the patient group (p = 0.006). No correlation was detected between NR-2 peptide levels and scores in the GCS or NIHSS. The results indicated that NR-2 was a potential biomarker elevated in the early phase of acute stroke, but had no correlation with the prognosis of acute stroke. Conclusion: Although our data shed light on the use of the NR-2 peptide level as a biomarker in the acute phase in patients with stroke, data are insufficient to predict prognosis. We think that larger, multicenter studies with longer follow-up periods are needed. | |
| dc.identifier.doi | 10.30565/medalanya.1116544 | |
| dc.identifier.endpage | 160 | en_US |
| dc.identifier.issue | 2 | en_US |
| dc.identifier.startpage | 145 | en_US |
| dc.identifier.uri | https://dergipark.org.tr/tr/download/article-file/2427261 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12868/1765 | |
| dc.identifier.volume | 6 | en_US |
| dc.language.iso | en | |
| dc.relation.ispartof | Acta Medica Alanya | |
| dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Başka Kurum Yazarı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Stroke | |
| dc.subject | NR-2 peptide | |
| dc.subject | Diagnosis | |
| dc.subject | Prognosis | |
| dc.subject | Biomarker | |
| dc.title | Is there a relationship between NR-2 antibody peptide level and diagnosis, prognosis and coma scores in acute ischemic stroke? | |
| dc.type | Article |
